Bendamustine, followed by obinutuzumab and idelalisib in chronic lymphocytic leukemia (CLL2-BCG): Final analysis of a multicenter, open-label phase-II-trial

MeSH terms

• Aged
• Antibodies, Monoclonal, Humanized* / administration & dosage
• Antibodies, Monoclonal, Humanized* / adverse effects
• Antibodies, Monoclonal, Humanized* / therapeutic use
• Antineoplastic Combined Chemotherapy Protocols* / administration & dosage
• Antineoplastic Combined Chemotherapy Protocols* / adverse effects
• Antineoplastic Combined Chemotherapy Protocols* / therapeutic use
• Bendamustine Hydrochloride* / administration & dosage
• Bendamustine Hydrochloride* / therapeutic use
• Female
• Humans
• Leukemia, Lymphocytic, Chronic, B-Cell* / drug therapy
• Male
• Middle Aged
• Purines* / administration & dosage
• Purines* / adverse effects
• Purines* / therapeutic use
• Quinazolinones* / administration & dosage
• Quinazolinones* / adverse effects
• Quinazolinones* / therapeutic use